Adults 18 to 75, any sex, with Type 2 Diabetes or Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Blood Glucose Incremental Area Under the CurvePrimary· 0 and 120 min after consumption of chocolate bar
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and after consumption of chocolates. Incremental area under the curve will calculate the glucose above baseline fasting values across 120 minutes.
Group
Value
95% CI
Dark Chocolate
240.5
± 55.81
Ross Dark Chocolate
83.81
± 46.18
Peak Blood Glucose ConcentrationSecondary· 0 and 120 minutes after consumption of chocolate bar
Highest blood glucose value measured after consumption of the chocolate bar
Group
Value
95% CI
Ross Dark Chocolate
10.6
± 2.9
Conventional Dark Chocolate
11.9
± 4.1
Peak Blood Glucose Concentration Above BaselineSecondary· Throughout study completion: 0-120 minutes after consumption of chocolate bar
Highest blood glucose value above fasting baseline after consumption of the chocolate bar
Group
Value
95% CI
Ross Dark Chocolate
2.2
± 2.2
Conventional Dark Chocolate
3.5
± 2.9
Blood GlucoseSecondary· 0 and 120 minutes
A self-monitoring blood glucose device (OneTouch Verio IQ® kit Blood glucose monitoring system) will be used to measure blood glucose levels before and after consumption of chocolates. Total area under the curve will calculate the glucose above zero across 120 minutes.
Group
Value
95% CI
Ross Dark Chocolate
1090.8
± 257.7
Conventional Dark Chocolate
1247.5
± 390.1
Taste Questionnaire - 0 to 100 Point ScaleSecondary· Throughout study completion:120 min after consumption of chocolate bar
Self-reported taste of chocolate bars will be assessed by questionnaire with ratings from awful (0), average (50) to fantastic (100).
Group
Value
95% CI
Ross Dark Chocolate
51.6
± 22
Conventional Dark Chocolate
66
± 18.5
Sponsor's own description
Diabetes is a growing concern in the world with an estimated 9.3% of adults, ages 20-79, with it in 2019, type 2 diabetes accounting for 90% of this total. A common recommendation for individuals with diabetes is to limit sugars and sweets as it may cause a high blood glucose response. As a result, chocolate is often avoided due to the sugar content; though, high-polyphenol chocolate may have a beneficial effect on hyperglycaemia and vascular function. The sugar-free chocolate from Ross Chocolates is formulated with a blend of inulin, erythritol, and stevia. These alternatives to sugar are not expected to cause a significant change in blood glucose levels following consumption. The main objective of this study is to verify glucose levels before and after consumption of Ross Chocolates' blend of sweeteners dark chocolate and conventional chocolate in people with diabetes.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06976255 — The Effect of Dark Chocolate and Cinnamon Sugars on Pain and Anxiety in University Students With Primary Dysmenorrhea
· NA
· completed
NCT05755217 — Renal Ultrasound Response After Chocolate Consumption
· NA
· recruiting
NCT05227248 — Chocolate Dynamic Vessel Analysis
· NA
· completed
NCT03945916 — Dark Chocolate and Exercise Performance in Hypoxia
· NA
· completed
NCT03326934 — Impact of Dark Chocolate on Visual Performance
· NA
· completed
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D
· Phase 1
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet
· NA
· recruiting
NCT07254689 — The Food for Health Study
· NA
· recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes
· Phase 4
· recruiting
Other University of British Columbia trials
Trials by the same sponsor.
NCT07340970 — Sensory Stimuli During Cesarean Delivery
· not yet recruiting
NCT07481201 — Phenylalanine Requirements in the Menstrual Phases
· NA
· not yet recruiting
NCT07492095 — Leucine Requirements in School-Age Children
· NA
· not yet recruiting
NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI
· NA
· recruiting
NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04847999.